Spots Global Cancer Trial Database for A Study of Apatinib in Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of Apatinib in Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck
Official Title: Phase II Study of Apatinib Mesylate Administered as a Daily Oral Treatment in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck
Study ID: NCT02775370
Conditions
Interventions
Study Description
Brief Summary: This is a non-randomized, phase II, open label study of Apatinib Mesylate in patients with Head and neck recurrent/metastatic adenoid cystic carcinoma (ACC). The primary purpose of this study is to evaluate the efficacy and safety of Apatinib Mesylate in patients with ACC.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Shanghai ninth people's hospital, Shanghai, Shanghai, China
Contact Details
Name: Chenping Zhang, M.D.
Affiliation: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Role: PRINCIPAL_INVESTIGATOR
Name: Guopei Zhu, M.D.
Affiliation: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
